U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C4H3F7O
Molecular Weight 200.0548
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SEVOFLURANE

SMILES

FCOC(C(F)(F)F)C(F)(F)F

InChI

InChIKey=DFEYYRMXOJXZRJ-UHFFFAOYSA-N
InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2

HIDE SMILES / InChI

Molecular Formula C4H3F7O
Molecular Weight 200.0548
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/ultane-drug.htm https://www.drugs.com/cdi/sevoflurane.html http://www.wikidoc.org/index.php/Sevoflurane

Sevoflurane is a general anesthetic that is FDA approved for the induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Sevoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sevoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase and also binds to the GABA receptor. Common adverse reactions include cardiovascular: bradyarrhythmia, hypotension, gastrointestinal: nausea, vomiting, neurologic: somnolence, psychiatric: agitation, respiratory: cough, interrupted breathing and other: shivering.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
ULTANE

Approved Use

Sevoflurane, USP is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. Sevoflurane, USP should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. Since level of anesthesia may be altered rapidly, only vaporizers producing predictable concentrations of sevoflurane, USP should be used.

Launch Date

8.0248321E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
25.6 μM
1.7 % single, respiratory
dose: 1.7 %
route of administration: Respiratory
experiment type: SINGLE
co-administered:
FLUORIDE ION plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
26.1 μM
2.1 % single, respiratory
dose: 2.1 %
route of administration: Respiratory
experiment type: SINGLE
co-administered:
FLUORIDE ION plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
24 h
1.7 % single, respiratory
dose: 1.7 %
route of administration: Respiratory
experiment type: SINGLE
co-administered:
FLUORIDE ION plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
33 h
2.1 % single, respiratory
dose: 2.1 %
route of administration: Respiratory
experiment type: SINGLE
co-administered:
FLUORIDE ION plasma
Homo sapiens
population: UNHEALTHY
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Population Size: 118
Sources:
Other AEs: Bradycardia, Hypotension...
Other AEs:
Bradycardia (5%)
Hypotension (4%)
Tachycardia (2%)
Agitation (7%)
Laryngospasm (8%)
Airways obstruction (8%)
Breath holding (5%)
Cough increased (5%)
Sources:
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Disc. AE: Disinhibition...
Other AEs: Coughing, Laryngospasm...
AEs leading to
discontinuation/dose reduction:
Disinhibition (35 patients)
Other AEs:
Coughing (6 patients)
Laryngospasm (1 patient)
Breath holding (4 patients)
Shivering (8 patients)
Apnea (6 patients)
Bradycardia (1 patient)
Tachycardia (1 patient)
Hypertension (1 patient)
Anxiety (1 patient)
Dizziness (4 patients)
Tinnitus (1 patient)
Sources:
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Other AEs: Fever, Shivering...
Other AEs:
Fever (1%)
Shivering (6%)
Hypothermia (1%)
Movements involuntary (1%)
Headache (1%)
Hypotension (11%)
Hypertension (2%)
Bradycardia (5%)
Tachycardia (2%)
Somnolence (9%)
Agitation (9%)
Dizziness (4%)
Increased salivation (4%)
Nausea (2%)
Vomiting (18%)
Cough increased (11%)
Breath holding (2%)
Laryngospasm (2%)
Sources:
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, child
n = 507
Health Status: unhealthy
Condition: surgical procedures
Age Group: child
Population Size: 507
Sources:
Other AEs: Tachycardia, Hypotension...
Other AEs:
Tachycardia (6%)
Hypotension (4%)
Agitation (15%)
Breath holding (5%)
Cough increased (5%)
Laryngospasm (3%)
Apnea (2%)
Increased salivation (2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Tachycardia 2%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Population Size: 118
Sources:
Hypotension 4%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Population Size: 118
Sources:
Bradycardia 5%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Population Size: 118
Sources:
Breath holding 5%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Population Size: 118
Sources:
Cough increased 5%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Population Size: 118
Sources:
Agitation 7%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Population Size: 118
Sources:
Airways obstruction 8%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Population Size: 118
Sources:
Laryngospasm 8%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, adult
n = 118
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Population Size: 118
Sources:
Anxiety 1 patient
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Bradycardia 1 patient
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Hypertension 1 patient
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Laryngospasm 1 patient
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Tachycardia 1 patient
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Tinnitus 1 patient
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Disinhibition 35 patients
Disc. AE
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Breath holding 4 patients
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Dizziness 4 patients
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Apnea 6 patients
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Coughing 6 patients
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Shivering 8 patients
1 MAC single, respiratory
Recommended
Dose: 1 MAC
Route: respiratory
Route: single
Dose: 1 MAC
Sources:
unhealthy, adult
n = 117
Health Status: unhealthy
Condition: surgical procedures
Age Group: adult
Sex: M+F
Population Size: 117
Sources:
Fever 1%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Headache 1%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Hypothermia 1%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Movements involuntary 1%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Cough increased 11%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Hypotension 11%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Vomiting 18%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Breath holding 2%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Hypertension 2%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Laryngospasm 2%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Nausea 2%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Tachycardia 2%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Dizziness 4%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Increased salivation 4%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Bradycardia 5%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Shivering 6%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Agitation 9%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Somnolence 9%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, all ages
n = 2906
Health Status: unhealthy
Condition: surgical procedures
Age Group: all ages
Population Size: 2906
Sources:
Agitation 15%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, child
n = 507
Health Status: unhealthy
Condition: surgical procedures
Age Group: child
Population Size: 507
Sources:
Apnea 2%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, child
n = 507
Health Status: unhealthy
Condition: surgical procedures
Age Group: child
Population Size: 507
Sources:
Increased salivation 2%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, child
n = 507
Health Status: unhealthy
Condition: surgical procedures
Age Group: child
Population Size: 507
Sources:
Laryngospasm 3%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, child
n = 507
Health Status: unhealthy
Condition: surgical procedures
Age Group: child
Population Size: 507
Sources:
Hypotension 4%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, child
n = 507
Health Status: unhealthy
Condition: surgical procedures
Age Group: child
Population Size: 507
Sources:
Breath holding 5%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, child
n = 507
Health Status: unhealthy
Condition: surgical procedures
Age Group: child
Population Size: 507
Sources:
Cough increased 5%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, child
n = 507
Health Status: unhealthy
Condition: surgical procedures
Age Group: child
Population Size: 507
Sources:
Tachycardia 6%
3 % single, respiratory (max)
Recommended
Dose: 3 %
Route: respiratory
Route: single
Dose: 3 %
Sources:
unhealthy, child
n = 507
Health Status: unhealthy
Condition: surgical procedures
Age Group: child
Population Size: 507
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Inhibition 1000 uM]
Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Different inhibitory effects of volatile anesthetics on T- and L-type voltage-dependent Ca2+ channels in porcine tracheal and bronchial smooth muscles.
2001 Apr
Minimum alveolar concentration (MAC) of xenon with sevoflurane in humans.
2001 Apr
Cost optimization in anaesthesia.
2001 Apr
Influence of aortic blood flow velocity on changes of middle cerebral artery blood flow velocity during isoflurane and sevoflurane anaesthesia.
2001 Apr
Volatile anaesthetics restore bradykinin and serotonin-induced coronary vasodilation after blocking nitric oxide synthase: lack of anaesthetic effects on KATP channels and prostaglandin pathways.
2001 Apr
The effects of volatile anesthetics on the Q-Tc interval.
2001 Apr
The effects of sevoflurane and isoflurane on intracranial pressure and cerebral perfusion pressure after diffuse brain injury in rats.
2001 Apr
The use of sevoflurane in acute intermittent porphyria.
2001 Apr
Comparison of sevoflurane-nitrous oxide anaesthesia with the conventional intravenous-inhalational technique using bispectral index monitoring.
2001 Apr
Ketorolac is not nephrotoxic in connection with sevoflurane anesthesia in patients undergoing breast surgery.
2001 Apr
Anaesthesia in a child with autosomal recessive omodysplasia.
2001 Feb
[Anesthetic management for the correction of pectus excavatum using pectus bar under video-assistance].
2001 Feb
Can anesthesiologic strategies for caesarean section influence newborn jaundice? A retrospective and prospective study.
2001 Feb
Protective effects of volatile agents against methacholine-induced bronchoconstriction in rats.
2001 Feb
Agent-selective effects of volatile anesthetics on GABAA receptor-mediated synaptic inhibition in hippocampal interneurons.
2001 Feb
Absence of direct antioxidant effects from volatile anesthetics in primary mixed neuronal-glial cultures.
2001 Feb
Cardiovascular effects of sevoflurane, isoflurane, halothane, and fentanyl-midazolam in children with congenital heart disease: an echocardiographic study of myocardial contractility and hemodynamics.
2001 Feb
Desflurane or sevoflurane for gynaecological day-case anaesthesia with spontaneous respiration?
2001 Feb
Clinical evaluation of the Mapleson theoretical ideal fresh gas flow sequence at the start of low-flow anaesthesia with isoflurane, sevoflurane and desflurane.
2001 Feb
Sevoflurane--nitrous oxide anaesthesia supplemented with remifentanil: effect on recovery and cognitive function.
2001 Feb
Reversal of rocuronium with edrophonium during propofol versus sevoflurane anesthesia.
2001 Feb
Quantitative determination of vapor-phase compound A in sevoflurane anesthesia using gas chromatography-mass spectrometry.
2001 Feb
Endotracheal intubation with thiopental/succinylcholine or sevoflurane-nitrous oxide anesthesia in adults: a comparative study.
2001 Feb
Regulation of perfusion pressure during cardiopulmonary bypass using sevoflurane.
2001 Jan
[Epileptoform EEG activity: occurrence under sevoflurane and not during propofol application].
2001 Jan
High concentration sevoflurane induction of anesthesia accelerates onset of vecuronium neuromuscular blockade.
2001 Jan
[Hydrothorax during diagnostic laparoscopy].
2001 Jan
[Pulmonary embolism during laparoscopic cholecystectomy detected by sudden decrease in end-tidal carbon dioxide pressure].
2001 Jan
[Anesthesia for emergency surgery in a patient with Shy-Drager syndrome].
2001 Jan
Effect of smoking on induction of anaesthesia with sevoflurane.
2001 Jan
Respiratory reflexes in response to upper-airway administration of sevoflurane and isoflurane in anesthetized, spontaneously breathing dogs.
2001 Jan-Feb
Continuous thoracic epidural anesthesia with 0.2% ropivacaine versus general anesthesia for perioperative management of modified radical mastectomy.
2001 Jun
Hepatic failure in a child after acetaminophen and sevoflurane exposure.
2001 Jun
[The effect of anesthetic technique on recovery from neuromuscular blockade with cisatracurium].
2001 Mar
[Is the use of sevoflurane in closed circuit in pediatric anesthesia really an economy?].
2001 Mar
[Low alkali-hydroxide content in soda limes does not lead to reduction of compound A formation from sevoflurane during low-flow anesthesia].
2001 Mar
Halothane: the last word?
2001 Mar
Halothane: the last word?
2001 Mar
A comparison of the respiratory effects of high concentrations of halothane and sevoflurane.
2001 Mar
Effects of i.v. metoclopramide, atropine and their combination on gastric insufflation in children anaesthetized with sevoflurane and nitrous oxide.
2001 Mar
The effects of low-flow sevoflurane and isoflurane anesthesia on renal function in patients with stable moderate renal insufficiency.
2001 Mar
Reduced isoflurane consumption with bispectral index monitoring.
2001 Mar
Effect of sevoflurane on intracranial pressure and cardiovascular function in rabbits with experimental intracerebral haematoma.
2001 Mar-Apr
Postoperative nausea and vomiting in paediatric ambulatory surgery: sevoflurane versus spinal anaesthesia with propofol sedation.
2001 May
Preoperative small-dose ketamine prevented tourniquet-induced arterial pressure increase in orthopedic patients under general anesthesia.
2001 May
Modulation of NMDA receptor function by ketamine and magnesium. Part II: interactions with volatile anesthetics.
2001 May
The effect of intranasal fentanyl on the emergence characteristics after sevoflurane anesthesia in children undergoing surgery for bilateral myringotomy tube placement.
2001 May
The safety and efficacy of sevoflurane anesthesia in infants and children with congenital heart disease.
2001 May
Sevoflurane protects stunned myocardium through activation of mitochondrial ATP-sensitive potassium channels.
2001 May
Comparison of genotoxicity of sevoflurane and isoflurane in human lymphocytes studied in vivo using the comet assay.
2001 May 31
Patents

Sample Use Guides

Surgical levels of anesthesia can usually be achieved with concentrations of 0.5 - 3% sevoflurane with or without the concomitant use of nitrous oxide.
Route of Administration: Respiratory
Currents elicited by GABA 0.01 mM were increased by low sevoflurane concentrations to 183% and decreased by high sevoflurane concentrations (> 1 mM) to 34% (P < 0.05). Ten- to 90%-rise times of the currents were reduced by sevoflurane concentration dependently. At GABA (1 mM), peak currents and 10-90%-rise times decreased with increasing sevoflurane concentrations.
Substance Class Chemical
Created
by admin
on Wed Jul 05 22:53:16 UTC 2023
Edited
by admin
on Wed Jul 05 22:53:16 UTC 2023
Record UNII
38LVP0K73A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SEVOFLURANE
INN   USAN  
Official Name English
SEVOCALM
Brand Name English
SEVOFLURANE [VANDF]
Common Name English
SEVOFLO
Brand Name English
SEVOFLURANE [EMA EPAR VETERINARY]
Common Name English
SEVOFLURANE [USAN]
Common Name English
SEVOFLURANE [USP MONOGRAPH]
Common Name English
SEVOFLURANE [EP MONOGRAPH]
Common Name English
SEVOFLURANE [USP-RS]
Common Name English
SEVORANE
Brand Name English
Sevoflurane [WHO-DD]
Common Name English
SEVOFLURANE [MART.]
Common Name English
SEVOFLURANE [MI]
Common Name English
MR6S4
Code English
ULTANE
Brand Name English
SEVOFLURANE [USP IMPURITY]
Common Name English
NSC-760367
Code English
SEVOFLURANE [ORANGE BOOK]
Common Name English
MR-6S4
Code English
SEVOFLURANE [GREEN BOOK]
Common Name English
PROPANE, 1,1,1,3,3,3-HEXAFLUORO-2-(FLUOROMETHOXY)-
Systematic Name English
SEVOFLURANE [JAN]
Common Name English
sevoflurane [INN]
Common Name English
SEVOFLURANE [EP IMPURITY]
Common Name English
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
Systematic Name English
Classification Tree Code System Code
WHO-ATC N01AB08
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
WHO-VATC QN01AB08
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
EMA VETERINARY ASSESSMENT REPORTS SEVOHALE [AUTHORIZED]
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
NDF-RT N0000175681
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
NCI_THESAURUS C245
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
NDF-RT N0000175975
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
EMA VETERINARY ASSESSMENT REPORTS SEVOFLO [AUTHORIZED]
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
LIVERTOX NBK548737
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
Code System Code Type Description
CHEBI
9130
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
IUPHAR
7296
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
PUBCHEM
5206
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
CAS
28523-86-6
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
MESH
C009250
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
MERCK INDEX
M9884
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY Merck Index
NSC
760367
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
WIKIPEDIA
SEVOFLURANE
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
DAILYMED
38LVP0K73A
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
RS_ITEM_NUM
1612540
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
SMS_ID
100000092425
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
INN
3028
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
DRUG CENTRAL
2439
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
EPA CompTox
DTXSID8046614
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
ChEMBL
CHEMBL1200694
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
LACTMED
Sevoflurane
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
NCI_THESAURUS
C47717
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
RXCUI
36453
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY RxNorm
FDA UNII
38LVP0K73A
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
HSDB
8059
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
DRUG BANK
DB01236
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
EVMPD
SUB10506MIG
Created by admin on Wed Jul 05 22:53:16 UTC 2023 , Edited by admin on Wed Jul 05 22:53:16 UTC 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
TARGET -> AGONIST
TARGET -> INHIBITOR
TARGET -> AGONIST
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
EP
IMPURITY -> PARENT
EP
Related Record Type Details
ACTIVE MOIETY